Otsuka America Pharmaceutical, Inc. (OAPI)

At the Cutting-edge of the Healthcare Industry

It takes a huge amount of expertise to bring a new medicine to market. That’s exactly what Otsuka America Pharmaceutical, Inc (OAPI) has been providing in the United States since 1989.  OAPI, part of the Otsuka group of companies, oversees commercial activities in the U.S., focusing on a diverse portfolio of products in neuroscience, oncology and cardio-renal. OAPI not only strives to develop and deliver first class medicines, but also to bring first class people into the Otsuka family. Our reputation for market knowledge and a thorough understanding of clinical practice is why we are a magnet for talent.  At OAPI, we always want to be at the cutting-edge of the healthcare industry. As a result, we empower our people to push boundaries to be as creative and innovative as they can be, using the latest technology where possible. Our goal is to deliver the most efficient, and effective medicines, and the best value to our customers. We have a solid track record in commercializing products developed by Otsuka, as well as in-licensed products, over the last 25 years. The future looks even more exciting, with numerous new products under development at our sister company, Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Recent alliances with other pharma companies, as well as strategic acquisitions by the Otsuka Group, may further enhance our ability to offer new products to customers and, ultimately, millions of patients with unmet medical needs.